Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (161.3), the stock would be worth ¥23.19 (1% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 162.7 | ¥23.4 |
0%
|
| 3-Year Average | 161.3 | ¥23.19 |
-1%
|
| 5-Year Average | 155.9 | ¥22.42 |
-4%
|
| Industry Average | 33.5 | ¥4.82 |
-79%
|
| Country Average | 29.6 | ¥4.26 |
-82%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
¥10.9B
|
/ |
Jul 2025
¥67.7m
|
= |
|
|
¥10.9B
|
/ |
Dec 2025
¥67.3m
|
= |
|
|
¥10.9B
|
/ |
Dec 2026
¥90.3m
|
= |
|
|
¥10.9B
|
/ |
Dec 2027
¥137.8m
|
= |
|
|
¥10.9B
|
/ |
Dec 2028
¥166.4m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
S
|
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
|
11B CNY | 162.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.1 |
| Median | 29.6 |
| 70th Percentile | 57.7 |
| Max | 43 569.3 |
Other Multiples
Shanghai MicroPort EP Medtech Co Ltd
Glance View
Shanghai MicroPort EP Medtech Co. Ltd. has carved a distinct niche for itself within the rapidly evolving medical device industry, primarily focusing on electrophysiology. This innovative field deals with diagnosing and treating arrhythmias—irregular heartbeats that affect countless individuals globally. MicroPort EP's flagship products include advanced catheter-based systems and cardiac mapping technologies that physicians utilize to pinpoint and correct these heart rhythm disorders. Their solutions are intricately designed to improve the accuracy and effectiveness of ablation procedures, allowing for non-invasive interventions that can significantly enhance patient outcomes. By capitalizing on the increasing prevalence of cardiovascular ailments and the push towards less invasive medical treatments, the company has positioned itself as a pivotal player in the healthcare sector, gaining a competitive edge with its sophisticated R&D capabilities and product innovation. The company's revenue model revolves around the development, manufacturing, and sales of its proprietary electrophysiology devices. By investing heavily in research and development, MicroPort EP continually advances its product offerings, aiming to stay ahead of its competitors and meet the growing demands of healthcare professionals and patients alike. Sales are driven both domestically, within China's burgeoning healthcare market, and internationally, tapping into the global need for cutting-edge cardiac solutions. The integration of technology and healthcare expertise underscores their commitment to quality and innovation, ensuring a sustainable model as they advance in this niche sector. Ultimately, their financial performance reflects a strategic alignment with health trends and technological progress, allowing them to capture value in a market poised for significant growth.